International Order Win
Panacea Biotec UNICEF bOPV Order: Secures ₹78.24 Crore Vaccine Supply Award for 2028
NSE
panaceabio
BSE
531349
- Panacea Biotec Limited has received a Letter of Award (LoA) from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of bivalent Oral Polio Vaccine (bOPV) worth approximately US$8.205 million (₹78.24 crore) during Calendar Year 2028.
- The award forms part of the company’s existing long-term agreement with UNICEF covering the period from April 1, 2026, to March 31, 2030.
PRICE-SENSITIVE TRIGGER
Event: Panacea Biotec received a Letter of Award from UNICEF for the supply of bivalent Oral Polio Vaccine (bOPV).
Type: International Order Win
Impact: Positive
Immediate Effect: The order strengthens Panacea Biotec’s international vaccine business, enhances revenue visibility for Calendar Year 2028, and reinforces its long-standing relationship with UNICEF under the existing long-term supply agreement.
Metrics:
Key Order Metrics:
- Order Value: US$8.205 million (approximately ₹78.24 crore)
- Customer: UNICEF
- Product: Bivalent Oral Polio Vaccine (bOPV)
- Supply Period: Calendar Year 2028
- Contract Type: Letter of Award under an existing Long-Term Agreement
Highlight:
- Panacea Biotec secured a UNICEF vaccine supply order worth approximately ₹78.24 crore for Calendar Year 2028 under its ongoing long-term bOPV supply agreement.
What Happened ?
Panacea Biotec informed the stock exchanges that it has received a new Letter of Award from UNICEF for the supply of bivalent Oral Polio Vaccine (bOPV) in 10-dose and 20-dose presentations during Calendar Year 2028.
The award is part of the company’s previously announced long-term agreement with UNICEF, under which Panacea supplies bOPV from April 2026 through March 2030.
key details
Order Highlights:
- Received a Letter of Award from UNICEF.
- Order covers the supply of bivalent Oral Polio Vaccine (bOPV).
- Includes 10-dose and 20-dose vaccine presentations.
- Order value stands at approximately US$8.205 million (₹78.24 crore).
- Supplies are scheduled for Calendar Year 2028.
- The award is issued under Panacea Biotec’s previously signed Long-Term Agreement with UNICEF.
Strategic Significance:
- Reinforces Panacea Biotec’s position as a global supplier of oral polio vaccines.
- Extends the execution of the existing UNICEF long-term contract into Calendar Year 2028.
- Strengthens international business and provides additional revenue visibility.
- Demonstrates continued confidence from UNICEF in the company’s vaccine manufacturing capabilities.
Note:
- According to the disclosure, the order has been awarded by an international entity (UNICEF), will be executed during Calendar Year 2028, and is not a related-party transaction.
- The company also confirmed that neither its promoters nor promoter group have any interest in the awarding entity.
Risk Analysis
Summary:
- The UNICEF order enhances Panacea Biotec’s order book and international presence. However, execution remains subject to the conditions of the long-term agreement and timely vaccine supply during Calendar Year 2028.
Key Risks:
- Successful execution of vaccine supplies within the scheduled period.
- Manufacturing and regulatory compliance must be maintained.
- International procurement schedules may change based on global immunization requirements.
- Revenue recognition depends on successful delivery under contract terms.
Worst Case:
- Any production delays, regulatory issues, or changes in UNICEF procurement schedules could postpone execution or revenue recognition from the award.
Risk Level: Low
Company Commentary
- Panacea Biotec stated that the award has been received under the company’s existing long-term agreement with UNICEF.
- The company confirmed that the order covers the supply of bivalent Oral Polio Vaccine (bOPV) during Calendar Year 2028.
- The disclosure also confirmed that the transaction is not a related-party transaction, and the promoters have no interest in UNICEF.
Official Exchange Filing: Panacea Biotec Limited
